ArticleNature reviews. Cancer2018
Publisher Correction: Oncolytic viruses as engineering platforms for combination immunotherapy.
Article in Nature reviews. Cancer, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Alliance between titans: combination strategies of CAR-T cell therapy and oncolytic virus for the treatment of hematological malignancies.Annals of hematology · 2024Review
- The role of pyroptosis and gasdermin family in tumor progression and immune microenvironment.Experimental hematology & oncology · 2023Review
- Oncolytic adenoviruses expressing checkpoint inhibitors for cancer therapy.Signal transduction and targeted therapy · 2023Article
- Bluetongue Viruses Act as Novel Oncolytic Viruses to Effectively Inhibit Human Renal Cancer Cell Growth In Vitro and In Vivo.Medical science monitor : international medical journal of experimental and clinical research · 2021Article
- DNT Cell-based Immunotherapy: Progress and Applications.Journal of Cancer · 2020Review
- Article
Corrections and comments
- Erratum for
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In the online html version of this article, the affiliations for Jessica L. Pettigrew and John C. Bell were not correct. Jessica L. Pettigrew is at the Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada and John C. Bell is at the Center for Innovative Cancer Therapeutics, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada. This is correct in the print and PDF versions of the article and has been corrected in the html version.
Identifiers
29728690What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.